Latest Financial Results
Q1 2023
Quarter Ended Mar 31, 2023
$337.2M
Total revenue of $337.2 million, up 28% from $263.3 million for the prior-year quarter$14.6M
Net income attributable to ApolloMed of $14.6 million, up 3% from $14.3 million for the prior-year quarter$0.31
Earnings per share - diluted ("EPS - diluted") of $0.31For complete information regarding our financials, see our periodic filings